Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

IL-4 Is a Key Requirement for IL-4- and IL-4/IL-13-Expressing CD4 Th2 Subsets in Lung and Skin.

Prout MS, Kyle RL, Ronchese F, Le Gros G.

Front Immunol. 2018 Jun 1;9:1211. doi: 10.3389/fimmu.2018.01211. eCollection 2018.

2.

Clec9A+ Dendritic Cells Are Not Essential for Antitumor CD8+ T Cell Responses Induced by Poly I:C Immunotherapy.

Gilfillan CB, Kuhn S, Baey C, Hyde EJ, Yang J, Ruedl C, Ronchese F.

J Immunol. 2018 Apr 15;200(8):2978-2986. doi: 10.4049/jimmunol.1701593. Epub 2018 Mar 5.

PMID:
29507107
3.

Thymic stromal lymphopoietin drives the development of IL-13+ Th2 cells.

Ochiai S, Jagot F, Kyle RL, Hyde E, White RF, Prout M, Schmidt AJ, Yamane H, Lamiable O, Le Gros G, Ronchese F.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1033-1038. doi: 10.1073/pnas.1714348115. Epub 2018 Jan 16.

4.

Serum dehydroepiandrosterone sulphate, psychosocial factors and musculoskeletal pain in workers.

Marinelli A, Prodi A, Pesel G, Ronchese F, Bovenzi M, Negro C, Larese Filon F.

Occup Med (Lond). 2017 Dec 30;67(9):684-686. doi: 10.1093/occmed/kqx159.

PMID:
29281066
5.

Toll-Like Receptor 4, but Not Neutrophil Extracellular Traps, Promote IFN Type I Expression to Enhance Th2 Responses to Nippostrongylus brasiliensis.

Pellefigues C, Tang SC, Schmidt A, White RF, Lamiable O, Connor LM, Ruedl C, Dobrucki J, Le Gros G, Ronchese F.

Front Immunol. 2017 Nov 16;8:1575. doi: 10.3389/fimmu.2017.01575. eCollection 2017.

6.

Investigation of chimeric reads using the MinION.

White R, Pellefigues C, Ronchese F, Lamiable O, Eccles D.

Version 2. F1000Res. 2017 May 5 [revised 2017 Jan 1];6:631. doi: 10.12688/f1000research.11547.2. eCollection 2017.

7.

Fetal dendritic cells give mum a break.

Connor LM, Lamiable O, Ronchese F.

Immunol Cell Biol. 2017 Aug;95(7):575-576. doi: 10.1038/icb.2017.46. Epub 2017 Jul 18. No abstract available.

PMID:
28741621
8.

Type I interferon is required for T helper (Th) 2 induction by dendritic cells.

Webb LM, Lundie RJ, Borger JG, Brown SL, Connor LM, Cartwright AN, Dougall AM, Wilbers RH, Cook PC, Jackson-Jones LH, Phythian-Adams AT, Johansson C, Davis DM, Dewals BG, Ronchese F, MacDonald AS.

EMBO J. 2017 Aug 15;36(16):2404-2418. doi: 10.15252/embj.201695345. Epub 2017 Jul 17.

9.

Th2 responses are primed by skin dendritic cells with distinct transcriptional profiles.

Connor LM, Tang SC, Cognard E, Ochiai S, Hilligan KL, Old SI, Pellefigues C, White RF, Patel D, Smith AA, Eccles DA, Lamiable O, McConnell MJ, Ronchese F.

J Exp Med. 2017 Jan;214(1):125-142. doi: 10.1084/jem.20160470. Epub 2016 Dec 2.

10.

Conditions for the generation of cytotoxic CD4(+) Th cells that enhance CD8(+) CTL-mediated tumor regression.

Li K, Baird M, Yang J, Jackson C, Ronchese F, Young S.

Clin Transl Immunology. 2016 Aug 12;5(8):e95. doi: 10.1038/cti.2016.46. eCollection 2016 Aug.

11.

Activation-Induced TIM-4 Expression Identifies Differential Responsiveness of Intestinal CD103+ CD11b+ Dendritic Cells to a Mucosal Adjuvant.

Hilligan KL, Connor LM, Schmidt AJ, Ronchese F.

PLoS One. 2016 Jul 5;11(7):e0158775. doi: 10.1371/journal.pone.0158775. eCollection 2016.

12.

Monocyte-Derived Dendritic Cells Are Essential for CD8(+) T Cell Activation and Antitumor Responses After Local Immunotherapy.

Kuhn S, Yang J, Ronchese F.

Front Immunol. 2015 Nov 23;6:584. doi: 10.3389/fimmu.2015.00584. eCollection 2015.

13.

Monosodium Urate Crystals Induce Upregulation of NK1.1-Dependent Killing by Macrophages and Support Tumor-Resident NK1.1+ Monocyte/Macrophage Populations in Antitumor Therapy.

Steiger S, Kuhn S, Ronchese F, Harper JL.

J Immunol. 2015 Dec 1;195(11):5495-502. doi: 10.4049/jimmunol.1401755. Epub 2015 Nov 2.

14.

IL-1βR-dependent priming of antitumor CD4+ T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria.

Kuhn S, Yang J, Hyde EJ, Harper JL, Kirman JR, Ronchese F.

Oncoimmunology. 2015 Jun 26;4(10):e1042199. eCollection 2015 Oct.

15.

Antigen-specific cytotoxic T lymphocytes target airway CD103+ and CD11b+ dendritic cells to suppress allergic inflammation.

Daniels NJ, Hyde E, Ghosh S, Seo K, Price KM, Hoshino K, Kaisho T, Okada T, Ronchese F.

Mucosal Immunol. 2016 Jan;9(1):229-39. doi: 10.1038/mi.2015.55. Epub 2015 Jun 24.

PMID:
26104914
16.

The Differentiation of CD4(+) T-Helper Cell Subsets in the Context of Helminth Parasite Infection.

Bouchery T, Kyle R, Ronchese F, Le Gros G.

Front Immunol. 2014 Oct 15;5:487. doi: 10.3389/fimmu.2014.00487. eCollection 2014. Review.

17.

A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy.

Anderson RJ, Tang CW, Daniels NJ, Compton BJ, Hayman CM, Johnston KA, Knight DA, Gasser O, Poyntz HC, Ferguson PM, Larsen DS, Ronchese F, Painter GF, Hermans IF.

Nat Chem Biol. 2014 Nov;10(11):943-9. doi: 10.1038/nchembio.1640. Epub 2014 Oct 5.

PMID:
25282504
18.

Helminth-conditioned dendritic cells prime CD4+ T cells to IL-4 production in vivo.

Connor LM, Tang SC, Camberis M, Le Gros G, Ronchese F.

J Immunol. 2014 Sep 15;193(6):2709-17. doi: 10.4049/jimmunol.1400374. Epub 2014 Aug 8.

19.

CD326(lo)CD103(lo)CD11b(lo) dermal dendritic cells are activated by thymic stromal lymphopoietin during contact sensitization in mice.

Ochiai S, Roediger B, Abtin A, Shklovskaya E, Fazekas de St Groth B, Yamane H, Weninger W, Le Gros G, Ronchese F.

J Immunol. 2014 Sep 1;193(5):2504-11. doi: 10.4049/jimmunol.1400536. Epub 2014 Jul 23.

20.

Monocyte-derived dendritic cells: Emerging players in the antitumor immune response.

Kuhn S, Ronchese F.

Oncoimmunology. 2013 Nov 1;2(11):e26443. Epub 2013 Oct 9.

21.

Efficient depletion of chronic lymphocytic leukemia B cells using serial rounds of immunomagnetic depletion.

Weinkove R, Brooks CR, Carter JM, Hermans IF, Ronchese F.

J Immunol Methods. 2013 Oct 31;396(1-2):152-6. doi: 10.1016/j.jim.2013.07.004. Epub 2013 Jul 31.

PMID:
23911312
22.

The control of CD8+ T cell responses is preserved in perforin-deficient mice and released by depletion of CD4+CD25+ regulatory T cells.

Ataera H, Simkins HM, Hyde E, Yang J, Hermans IF, Petersen TR, Ronchese F.

J Leukoc Biol. 2013 Oct;94(4):825-33. doi: 10.1189/jlb.0413200. Epub 2013 Jul 24.

PMID:
23883515
23.

Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.

Kuhn S, Hyde EJ, Yang J, Rich FJ, Harper JL, Kirman JR, Ronchese F.

J Immunol. 2013 Aug 15;191(4):1984-92. doi: 10.4049/jimmunol.1301135. Epub 2013 Jul 15.

24.

Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions.

Zhi-Iong Ma J, Yang J, Qin JS, Richter A, Perret R, El-Deiry WS, Finnberg N, Ronchese F.

Oncoimmunology. 2012 Dec 1;1(9):1507-1516.

25.

[Occupational risks and health disorders in transport drivers].

Ronchese F, Bovenzi M.

G Ital Med Lav Ergon. 2012 Jul-Sep;34(3):352-9. Review. Italian.

PMID:
23213815
26.

Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.

Lim SN, Kuhn S, Hyde E, Ronchese F.

J Immunother. 2012 Nov-Dec;35(9):670-9. doi: 10.1097/CJI.0b013e318270e135.

PMID:
23090076
27.

Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.

Weinkove R, Brooks CR, Carter JM, Hermans IF, Ronchese F.

Haematologica. 2013 Mar;98(3):376-84. doi: 10.3324/haematol.2012.072835. Epub 2012 Oct 12.

28.

Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis.

Rich FJ, Kuhn S, Hyde EJ, Harper JL, Ronchese F, Kirman JR.

Cancer Immunol Immunother. 2012 Dec;61(12):2333-42. doi: 10.1007/s00262-012-1291-8. Epub 2012 Jun 20.

PMID:
22714285
29.

Murine CD4+ T cell responses are inhibited by cytotoxic T cell-mediated killing of dendritic cells and are restored by antigen transfer.

Ma JZ, Lim SN, Qin JS, Yang J, Enomoto N, Ruedl C, Ronchese F.

PLoS One. 2012;7(5):e37481. doi: 10.1371/journal.pone.0037481. Epub 2012 May 23.

30.

Allergen-specific CTL require perforin expression to suppress allergic airway inflammation.

Enomoto N, Hyde E, Ma JZ, Yang J, Forbes-Blom E, Delahunt B, Le Gros G, Ronchese F.

J Immunol. 2012 Feb 15;188(4):1734-41. doi: 10.4049/jimmunol.1102699. Epub 2012 Jan 16.

31.

[Study of peripheral sensorineural function in a cohort of dental hygienists].

Ronchese F, Bovenzi M.

G Ital Med Lav Ergon. 2011 Jul-Sep;33(3 Suppl):235-7. Italian.

PMID:
23393844
32.

Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells.

Ataera H, Hyde E, Price KM, Stoitzner P, Ronchese F.

PLoS One. 2011 Mar 3;6(3):e17515. doi: 10.1371/journal.pone.0017515.

33.

Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.

Simkins HM, Hyde E, Farrand KJ, Ong ML, Degli-Esposti MA, Hermans IF, Ronchese F.

J Leukoc Biol. 2011 May;89(5):753-62. doi: 10.1189/jlb.0910480. Epub 2011 Feb 4.

PMID:
21297009
34.

Frequency weightings of hand-transmitted vibration for predicting vibration-induced white finger.

Bovenzi M, Pinto I, Picciolo F, Mauro M, Ronchese F.

Scand J Work Environ Health. 2011 May;37(3):244-52. doi: 10.5271/sjweh.3129. Epub 2010 Nov 3.

35.

A longitudinal study of peripheral sensory function in vibration-exposed workers.

Bovenzi M, Ronchese F, Mauro M.

Int Arch Occup Environ Health. 2011 Mar;84(3):325-34. doi: 10.1007/s00420-010-0549-8. Epub 2010 May 23.

PMID:
20496077
36.

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.

Petersen TR, Sika-Paotonu D, Knight DA, Dickgreber N, Farrand KJ, Ronchese F, Hermans IF.

Immunol Cell Biol. 2010 Jul;88(5):596-604. doi: 10.1038/icb.2010.9. Epub 2010 Feb 9.

PMID:
20142835
37.

Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro.

Robinson MJ, Ronchese F, Miller JH, La Flamme AC.

Immunol Cell Biol. 2010 Mar-Apr;88(3):291-6. doi: 10.1038/icb.2009.96. Epub 2009 Dec 8.

PMID:
19997079
38.

Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.

Farrand KJ, Dickgreber N, Stoitzner P, Ronchese F, Petersen TR, Hermans IF.

J Immunol. 2009 Dec 15;183(12):7732-42. doi: 10.4049/jimmunol.0902707.

39.

[Neck and upper limb disorders caused by combined exposures to ergonomic risk factors and hand-transmitted vibration].

Bovenzi M, Mauro M, Ronchese F, Larese Filon F.

G Ital Med Lav Ergon. 2008 Jul-Sep;30(3 Suppl):39-45. Review. Italian.

PMID:
19288788
40.

Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy.

Dickgreber N, Stoitzner P, Bai Y, Price KM, Farrand KJ, Manning K, Angel CE, Dunbar PR, Ronchese F, Fraser JD, Bäckström BT, Hermans IF.

J Immunol. 2009 Feb 1;182(3):1260-9.

41.

Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo.

Andrew KA, Simkins HM, Witzel S, Perret R, Hudson J, Hermans IF, Ritchie DS, Yang J, Ronchese F.

J Immunol. 2008 Dec 15;181(12):8356-62.

42.

Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.

Perret R, Ronchese F.

Eur J Immunol. 2008 Oct;38(10):2886-95. doi: 10.1002/eji.200838483.

43.

Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response.

Peacey M, Wilson S, Perret R, Ronchese F, Ward VK, Young V, Young SL, Baird MA.

Vaccine. 2008 Oct 3;26(42):5334-7. doi: 10.1016/j.vaccine.2008.07.074. Epub 2008 Aug 14.

PMID:
18706958
44.

Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?

Perret R, Ronchese F.

Tissue Antigens. 2008 Sep;72(3):187-94. doi: 10.1111/j.1399-0039.2008.01088.x. Epub 2008 Jul 9. Review.

PMID:
18627571
45.

Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.

Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F.

Cancer Immunol Immunother. 2008 Nov;57(11):1665-73. doi: 10.1007/s00262-008-0487-4. Epub 2008 Mar 1.

PMID:
18311487
46.

Tumor immunotherapy by epicutaneous immunization requires langerhans cells.

Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, Kissenpfennig A, Hermans IF, Ronchese F.

J Immunol. 2008 Feb 1;180(3):1991-8.

47.

Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses.

Matthews KE, Qin JS, Yang J, Hermans IF, Palmowski MJ, Cerundolo V, Ronchese F.

J Immunol. 2007 Nov 1;179(9):5738-47.

48.
49.

Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors.

Huck SP, Tang SC, Andrew KA, Yang J, Harper JL, Ronchese F.

Cancer Immunol Immunother. 2008 Jan;57(1):63-71. Epub 2007 Jul 3.

PMID:
17609951
50.

Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism.

Watt V, Ronchese F, Ritchie D.

J Immunother. 2007 Apr;30(3):323-32.

PMID:
17414323

Supplemental Content

Loading ...
Support Center